ERBB2 and breast carcinoma: (13) analyzed two groups of patients, an OFS+tamoxifen (n = 260) and a sequential AC+tamoxifen (n = 260) group, among 994 patients with T1-2N0, HR+ HER2- breast cancer with propensity score matching and inverse probability weighting.